免疫学

Antibody (Ab) and nanobody (Nb) humanization is essential for reducing immunogenicity in therapeutic applications. HuDiff is an adaptive autoregressive diffusion approach that generates humanized antibodies and nanobodies from scratch using only complementarity-determining region sequences as input, eliminating the need for preexisting human templates. The method follows a two-stage training pipeline: pretraining on human antibody sequences to learn framework region patterns, followed by fine-tuning on target-species sequences. HuDiff-Ab processes paired heavy and light chains for conventional antibodies, while HuDiff-Nb can incorporate a specialized inpainting mode to preserve critical nanobody framework residues. This protocol provides a complete step-by-step guide for implementing HuDiff, covering data preparation, model training, and sequence generation.

Accurate, sensitive quantification of B-lineage cells is critical for pharmacodynamic evaluation of B cell–targeted therapies in lupus nephritis (LN) clinical trials. While high-dimensional discovery platforms offer broad profiling, they often lack the sensitivity, quantitative rigor, and throughput needed for precise cell enumeration in renal trial needle biopsies. Traditional immunostaining is hampered by CD20-directed therapeutic masking or downregulation, inadequate sensitivity of CD19 in FFPE tissue, and confounding renal tubular CD138 expression. This protocol details an automated, fit-for-purpose, 5-plex sequential tyramide signal amplification (TSA)-based immunofluorescence assay (CD38, CD79a, CD19, Ki-67, CD138) developed on the Ventana Discovery Ultra platform for deployment on single tissue sections. The workflow anchors B-cell detection on CD79a to ensure sensitivity and utilizes CD38 as an obligate co-marker for CD138+ antibody-secreting cells (ASCs) to definitively exclude the CD138+ epithelial background. Following acquisition via fluorescence whole-slide imaging, a digital analysis pipeline utilizing InstanSeg-based automated segmentation rigorously classifies cell phenotypes to generate precise spatial densities (cells/mm²). This validated protocol maximizes data yield from scarce clinical biopsies while providing high-precision quantitative monitoring of longitudinal therapeutic depletion in the renal microenvironment.

Surface receptor engagement governs T-cell activation. Since these surface receptors undergo extensive glycosylation, lectin-mediated crosslinking of these glycosylated surface receptors has the potential to modulate signaling. Here, we systematically evaluate the abilities of recombinant human galectins in triggering immune responses. We describe how to apply the human galectins to modulate Jurkat E6-1 cell activation by measuring the expression level of cellular surface CD69 and the mRNA of IL-2. To validate the protocol, we confirmed that galectin-3 and galectin-8 variants 1 and 2 reproducibly induce CD69 and IL-2 expression on Jurkat E6-1 cells. Our approach offers a galectin-based toolset to study how glycosylation modulates human adaptive immunity.

Cell therapy holds great promise for cancer immunotherapy, but its clinical efficacy is severely hindered by poor post-transplant cell survival, low homing efficiency, and host immune clearance. To address these challenges, this study develops a novel light-controlled immunotherapy strategy that integrates a red/far-red light genetic switch with single-cell encapsulation engineering. The red/far-red light (660/730 nm) reversible regulatory system enables precise spatiotemporal control over the expression of therapeutic proteins in engineered cells (e.g., CAR-T or engineered HEK 293T cells), allowing on-demand activation of anti-tumor immune responses. On this basis, a mild enzyme-mediated single-cell encapsulation technique is further employed to rapidly form a protective hydrogel coating in situ on the cell surface, thereby enhancing the survival of transplanted cells under hostile in vivo microenvironments. This strategy combines precise gene expression regulation with physical protection, improving therapeutic outcomes without the need for genomic modification of the cells. It provides a new paradigm for developing safe, controllable, and efficient cancer immunotherapy.

This protocol describes an optimized strategy for the efficient generation of peptide-loaded major histocompatibility complex (MHC) class II (pMHC) tetramers, which are essential tools for detecting and characterizing antigen-specific T cells in immunological research. Traditional methods require separate expression of MHC proteins followed by in vitro biotinylation—a multi-step process that is time-consuming and prone to protein loss. Here, we present an integrated approach based on co-expression of MHC monomers and BirA biotin ligase in Expi293F T cells, enabling site-specific biotinylation in vivo during protein synthesis. At the same time, the incorporation of a thrombin-cleavable class II–associated invariant chain peptide (CLIP) peptide into the MHC construct allows flexible loading of any antigenic peptide of interest without the need for re-cloning or re-expression of the MHC molecule. Pre-biotinylated MHC molecules are subsequently purified, loaded with antigenic peptides, and assembled into fluorescent tetramers via streptavidin conjugation. This streamlined workflow significantly reduces handling steps, improves protein yield, and enhances reproducibility. The resulting tetramers are suitable for sensitive detection and isolation of antigen-specific T cells by flow cytometry, supporting applications in T-cell immunogenicity studies, vaccine development, and autoimmune disease research.

Mitochondrial transplantation is an emerging strategy for cellular repair, yet its efficiency is often limited by poor targeting and environmental instability. This protocol details the fabrication and comprehensive characterization of neutrophil membrane-fused mitochondria (nMITO), a hybrid organelle platform designed to combine the metabolic vigor of natural mitochondria with the targeting and anti-inflammatory properties of neutrophil membranes. We describe an optimized workflow for mouse heart mitochondrial isolation, lipopolysaccharide (LPS)-activated neutrophil membrane (NEM) extraction, and the subsequent sonication-mediated fusion process. Characterization techniques include dynamic light scattering (DLS) for size and zeta potential, transmission electron microscopy (TEM) for ultrastructural integrity, and bioenergetic assays [ATP synthesis and tetramethylrhodamine methyl ester (TMRM)-based membrane potential] to ensure functional preservation.

Autoreactive CD4⁺ T cells are shaped by MHC class II–dependent selection, and HLA-DQ8 is a major susceptibility allele for type 1 diabetes and celiac disease. To define how HLA-DQ8 influences the autoreactive CD4⁺ T-cell repertoire, we generated T-cell hybridomas from HLA-DQ8 humanized mice using a BW5147 Nur77-GFP (BW-GFP) platform that enables sensitive quantification of antigen-induced T-cell receptor (TCR) signaling. The frequency of autoreactive conventional CD4⁺ hybridomas observed in HLA-DQ8 mice was higher than previously reported in C57BL/6 mice in our earlier study, suggesting that HLA-DQ8 shapes an autoreactive repertoire. However, because antigen presentation in this system is restricted by human HLA-DQ8 while hybridomas express murine CD4, we considered that CD4-MHC interspecies mismatch might affect signal strength and influence the apparent magnitude of autoreactivity. To address this limitation, we engineered a BW-GFP fusion partner expressing an optimized version of human CD4 (hCD4), restoring optimal CD4-HLA-DQ8 interactions. Hybridomas generated with this modified platform from both regulatory (Treg) and conventional (non-Treg) CD4⁺ T cells exhibited enhanced responses to HLA-DQ8/peptide complexes compared with hybridomas that do not express hCD4. This approach improves the reactivity and physiological accuracy of screening mouse-derived CD4 hybridomas specific to self and foreign antigens presented by human class II MHC complexes.

The binding of transmembrane (TM) ligands to their cognate TM receptors on neighboring cells governs intercellular adhesion and direct cell–cell communication. However, these interactions are difficult to study in vitro because they depend on membrane presentation, ligand orientation, receptor clustering, and avidity, features often not captured by soluble recombinant ligands or cell-free assays. Here, we describe a flow cytometry–based assay using fluorescent, lentiviral virus-like particles (VLPs) displaying TM ligands to quantify binding to their receptors on target cells. Fluorescent VLPs are generated in-house by plasmid transfection in HEK293T cells and enable direct fluorescent detection without fluorochrome-conjugated secondary antibodies. The system is modular and readily accommodates engineered ligand constructs, including patient-derived variants. We applied this platform to generate ICAM-1-displaying fluorescent VLPs and to study human LFA-1 function in patient-derived leukocytes. This protocol provides a detailed workflow for VLP production and in vitro binding assays, offering a simple, quantitative, and cost-effective approach for studying TM ligand–receptor interactions in a membrane context. The system is well-suited for mechanistic studies, functional assessment of patient-derived variants, and direct binding assays using patient-derived cells. Integrating the assay into multicolor flow cytometry panels enables simultaneous immunophenotyping and quantification of up to four ligand–receptor interactions at single-cell resolution.

Cyclic peptides are emerging as a promising class of recognition modules for chimeric antigen receptor (CAR) engineering. Compared with single-chain variable fragment (scFv)-based CARs, disulfide-directed multicyclic peptides (DDMPs) represent a novel alternative, offering a markedly smaller molecular size (<5 kDa), enhanced structural stability through disulfide-directed cyclization, and broad tolerance to sequence diversification that supports systematic affinity and specificity optimization. DDMP-based CAR T cells leverage these properties to mediate antigen-dependent cytotoxicity while exhibiting an attenuated cytokine secretion profile, supporting the development of potentially safer immunotherapies for solid tumors. Here, we present a comprehensive workflow spanning CAR construct design and generation through in vitro and in vivo functional evaluation. While DDMPs are used as the exemplar recognition module, sections A and C–L of the protocol are directly applicable to any CAR format, including scFv- and nanobody-based designs with minimal modifications, making the workflow accessible to the broader CAR T-cell research community. The protocol includes the generation of Jurkat NFAT reporter cell lines and luciferase-expressing tumor target lines, which are widely used in different assays. Together, these standardized readouts enable rigorous, objective comparison of CAR T-cell efficacy and safety across tumor models.

The PrimeFlow^TM assay is a flow cytometry–based method for the co-detection of RNAs and proteins in cells. When combined with cell characterization by immunophenotyping, PrimeFlow^TM can be used to simultaneously detect RNA and proteins in a cell type–specific manner in complex heterogeneous samples, offering an advantage over bulk tissue analysis methods. Here, we describe the implementation of the PrimeFlow^TM assay protocol for the detection of transgene mRNA and protein expression in spleen samples from mice treated in vivo with luciferase mRNA-lipid nanoparticles (LNPs). This protocol involves spleen tissue dissociation for cell isolation, followed by cell fixation and permeabilization to allow immunolabeling of intracellular luciferase protein. The immunophenotyping strategy is based on immunolabeling with mouse CD marker antibodies for the identification of T cells, B cells, monocytes, granulocytes/macrophages, NK cells, and non-hematopoietic cells. The RNAs of luciferase and a housekeeping gene, β-actin, are detected with sequence-specific probe sets by employing sequential oligonucleotide annealing steps and fluorescent labeling using a branched DNA (bDNA) technology. Samples are analyzed by flow cytometry. Based on our analysis, we conclude it is feasible to apply the PrimeFlow^TM approach for evaluating successful drug targeting to the cell types of interest and any potential differences in the kinetics of RNA delivery and protein expression in various tissue cells, supporting the discovery and development of RNA therapeutics.